首页> 美国卫生研究院文献>Journal of Clinical Translational Endocrinology >Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (50 years) obese patients with type 2 diabetes mellitus

【2h】

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (50 years) obese patients with type 2 diabetes mellitus

机译：胰高血糖素样肽1受体激动剂利西拉来与二肽基肽酶4抑制剂西他列汀在年轻（50岁）肥胖的2型糖尿病患者中的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

ObjectiveTo compare the efficacy and safety of the once-daily prandial glucagon-like peptide-1 receptor agonist lixisenatide with the dipeptidyl peptidase-4 inhibitor sitagliptin in patients aged <50 years affected by obesity and type 2 diabetes mellitus (T2DM).

机译：目的比较每日一次的餐后胰高血糖素样肽1受体激动剂利西拉来和二肽基肽酶4抑制剂西他列汀在肥胖和2型糖尿病（T2DM）患者中的年龄在50岁以下。

著录项

期刊名称 Journal of Clinical Translational Endocrinology
作者
Luc Van Gaal; Elisabeth Souhami; Tianyue Zhou; Ronnie Aronson;
展开▼
作者单位

展开▼
年(卷),期 2014(1),2
年度 2014
页码 31–37
总页数 7
原文格式 PDF
正文语种
中图分类基础医学;
关键词
Glycated hemoglobin (HbA1c) Body weight Postprandial plasma glucose (PPG);

机译：糖化血红蛋白（HbA1c）;体重;餐后血浆葡萄糖（PPG）;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (50 years) obese patients with type 2 diabetes mellitus [J] . Luc Van Gaal, Elisabeth Souhami, Tianyue Zhou, Journal of Clinical & Translational Endocrinology . 2014,第2期

机译：胰高血糖素样肽1受体激动剂利西拉来与二肽基肽酶4抑制剂西他列汀在年轻（<50岁）肥胖的2型糖尿病患者中的疗效和安全性
2. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials [J] . Tran Susan, Retnakaran Ravi, Zinman Bernard, Diabetes, obesity & metabolism . 2018,第Suppla1期

机译：胰高血糖素肽-1受体激动剂与二肽基肽酶-4抑制剂进行疗效，用于治疗2型糖尿病患者：随机临床试验的META分析
3. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis [J] . DeaconC.F., MannucciE., AhrénB. Diabetes, obesity & metabolism . 2012,第8期

机译：胰高血糖素样肽1受体激动剂和二肽基肽酶4抑制剂作为二甲双胍在2型糖尿病患者中的附加治疗的血糖功效-审查和荟萃分析
4. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis β-Cell Function and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter Prospective Observational Uncontrolled Study [O] . Yuya Tsurutani, Masao Omura, Yoko Matsuzawa, 2017

机译：二肽基肽酶-4抑制剂西格列汀对日本初治或对抗糖尿病药反应较差的2型糖尿病患者的动脉粥样硬化β细胞功能和血糖控制的疗效和安全性：多中心前瞻性观察性未经对照的研究
5. Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus [O] . Luc Van Gaal, Elisabeth Souhami, Tianyue Zhou, 2014

机译：胰高血糖素样肽-1受体激动剂利西拉来与二肽基肽酶-4抑制剂西他列汀在年轻（<50岁）肥胖2型糖尿病患者中的疗效和安全性

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (50 years) obese patients with type 2 diabetes mellitus

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅